LBLogan Brooks

Logan Brooks

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Logan Brooks has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Follow‐Up Bias in Tumor Dynamic Modeling: A Comparison of Classical and Neural‐ODE Approaches

    by David C. Turner, Mark Laurie, Shuhui Li, Huy X. Ngo, Chunze Li, Jin Y. Jin, James Lu, Logan Brooks

    Tumor dynamic models are vital for evaluating oncology treatments and guiding clinical drug development decisions. However, few studies rigorously assess their predictive capabilities, especially when forecasting tumor trajectories from clinical trials with short or inconsistent follow‐up across treatment arms. Poor predictive performance or biases related to follow‐up time could potentially limit the general utility of tumor growth inhibition (TGI) models. This study quantitatively evaluates prediction bias across several established tumor dynamic models, comparing five classical pharmacometric TGI models with the deep learning‐based Tumor Dynamic Neural‐ODE (TDNODE) framework. Using time‐truncated clinical trial data from 3106 patients with non‐small cell lung cancer (NSCLC) across four completed atezolizumab phase III studies, we consistently observed moderate‐to‐high positive bias in the predictions from pharmacometric models, particularly with more limited follow‐up. By examining the structures of these models and comparing them to observed data, we highlight how the assumed kinetic patterns potentially lead to biased parameter estimation and systemic overestimation of tumor size when applied to immature datasets. In contrast, the TDNODE framework, using deep learning, demonstrated promising early results, exhibiting improved predictive performance in the same evaluations. These findings underscore the critical need to address prediction bias in tumor dynamic modeling with immature data and to consider alternative approaches to established paradigms for certain drug development applications. This study also generally demonstrates the potential of novel methods, such as deep learning, to potentially enhance the reliability of tumor dynamics modeling, especially in challenging early‐phase clinical decision‐making scenarios.


  • Open Access

    Safety, Pharmacokinetics, and Immunogenicity of Astegolimab, an Anti‐ST2 Monoclonal Antibody, in Randomized, Phase I Clinical Studies

    by Wenhui Zhang, Dorothy Cheung, Alice Fong, Logan Brooks, Michele A. Grimbaldeston, Audrey Arjomandi, Xiaoying Yang, Ajit Dash, Hansen Wong, Jane R. Parnes, et al.

    Astegolimab, a fully human immunoglobulin G2 monoclonal antibody, binds with high affinity to ST2, the interleukin‐33 receptor, thereby blocking ST2/interleukin‐33 binding and subsequent inflammatory cascades involved in inflammatory diseases. Here, we present three randomized, double‐blind, placebo‐controlled, Phase I studies evaluating the safety, tolerability, pharmacokinetics, and immunogenicity of single‐ascending doses of astegolimab in healthy participants and patients with mild atopic asthma (NCT01928368), multiple‐ascending doses in healthy participants (NCT02170337), and single‐ascending doses in healthy Japanese and White adults. Overall, 152 participants were enrolled, randomized, and treated with single‐ or multiple‐ascending doses of astegolimab ( n = 112) or placebo ( n = 40) subcutaneously (2.1–560 mg) or intravenously (210 or 700 mg). No deaths, serious adverse events, or discontinuations due to adverse events occurred during the studies. No clinically meaningful differences in incidence of TEAEs were observed between treatment arms. Pharmacokinetic exposure increased more than dose proportionally over 2.1–420 mg for single‐ascending doses but were approximately dose proportional for single‐ and multiple‐ascending doses ≥ 70 mg following subcutaneous administration. No pharmacokinetic differences were observed based on ethnicity between Japanese and White participants following body weight adjustments. Incidence of antidrug antibodies to astegolimab in healthy participants in the single‐ and multiple‐ascending dose studies was 14%–23% and 33%–50% for subcutaneous and intravenous administration, respectively. Astegolimab was well tolerated in these Phase I studies with no safety concerns identified. Thus, further assessment of astegolimab in targeted patient populations was justified; the Phase IIb ALIENTO and Phase III ARNASA trials in patients with chronic obstructive pulmonary disease are ongoing.


  • Open Access

    Shap‐Cov: An Explainable Machine Learning Based Workflow for Rapid Covariate Identification in Population Modeling

    by Logan Brooks, Rashed Harun, Jin Y. Jin, James Lu

    Covariate identification in population pharmacokinetic/pharmacodynamic (popPK/PD) modeling is a key component in model development that is often prone to bias, time‐consuming, and even intractable when too many covariates or complicated models are being considered. Early work leveraging machine learning (ML) for covariate screening has shown promising results over traditional methods. In this work, we expand this effort by integrating explainable machine learning facilitated by Shapley Additive Explanations (SHAP) analysis and covariate uncertainty quantification as well as a formal framework for establishing statistical significance of covariate relationships. Finally, we have packaged the proposed methodology into a flexible set of functions (shap‐cov) to support popPK/PD modeling covariate identification.


  • Open Access

    Use of Real‐World Claims Data to Assess the Prevalence of Concomitant Medications to Inform Drug–Drug Interaction Risk in Target Patient Populations

    by Alice S. Tang, Logan Brooks, Denise M. Boudreau, Pascal Chanu, Amita Joshi, Bianca Vora, Rui Zhu

    A common issue in clinical drug development involves drug–drug interactions (DDI) that may lead to altered drug exposure and subsequent altered safety and efficacy of an investigational drug or concomitant medications (conmeds) in the target patient population. The drug development pipeline therefore involves DDI risk assessment of the investigational drug based on in vitro studies, in silico modeling, and clinical trials. Real‐world data (RWD), particularly claims databases with reliable information on pharmacy dispensing, provide an opportunity to understand conmeds usage in the target indication in a real‐world setting as one approach to assess potential DDI risk. We describe two cases of characterizing DDI‐related conmeds usage with a large closed US‐based claims database, IQVIA PharMetrics® Plus, and identified potential DDI risk for multiple sclerosis and hormone receptor‐positive breast cancer. For example, prevalent and chronic use of statins (atorvastatin and simvastatin), which are CYP3A4 substrates, were identified among both disease cases. Further examples, limitations, and future directions are also discussed. These insights can therefore help augment decision‐making during clinical drug research and development.


  • Open Access

    Deep‐NCA: A deep learning methodology for performing noncompartmental analysis of pharmacokinetic data

    by Gengbo Liu, Logan Brooks, John Canty, Dan Lu, Jin Y. Jin, James Lu

    Noncompartmental analysis (NCA) is a model‐independent approach for assessing pharmacokinetics (PKs). Although the existing NCA algorithms are very well‐established and widely utilized, they suffer from low accuracies in the setting of sparse PK samples. In response, we developed Deep‐NCA, a deep learning (DL) model to improve the prediction of key noncompartmental PK parameters. Our methodology utilizes synthetic PK data for model training and uses an innovative patient‐specific normalization method for data preprocessing. Deep‐NCA demonstrated adequate performance across six previously unseen simulated drugs under multiple dosing, showcasing effective generalization. Compared to traditional NCA, Deep‐NCA exhibited superior performance for sparse PK data. This study advances the application of DL to PK studies and introduces an effective method for handling sparse PK data. With further validation and refinement, Deep‐NCA could significantly enhance the efficiency of drug development by providing more accurate NCA estimates while requiring fewer PK samples.


  • Open Access

    gPKPDviz: A flexible R shiny tool for pharmacokinetic/pharmacodynamic simulations using mrgsolve

    by Tong Lu, Victor Poon, Logan Brooks, Erick Velasquez, Eric Anderson, Kyle Baron, Jin Y. Jin, Matts Kågedal

    GPKPDviz is a Shiny application (app) dedicated to real‐time simulation, visualization, and assessment of the pharmacokinetic/pharmacodynamic (PK/PD) models. Within the app, gPKPDviz is capable of generating virtual populations and complex dosing and sampling scenarios, which, together with the streamlined workflow, is designed to efficiently assess the impact of covariates and dosing regimens on PK/PD end points. The actual population data from clinical trials can be loaded into the app for simulation if desired. The app‐generated dosing regimens include single or multiple dosing, and more complex regimens, such as loading doses or intermittent dosing. When necessary, the dosing regimens can be defined externally and loaded to the app for simulation. Using mrgsolve as the simulation engine, gPKPDviz is typically used for population simulation, however, with a slight modification of the mrgsolve model, gPKPDviz is capable of performing individual simulations with individual post hoc parameters, individual dosing logs, and individual sampling timepoints through an external dataset. A built‐in text editor has a debugging feature for the mrgsolve model, providing the same error messages as model compilation in R. GPKPDviz has had stringent validation by comparing simulation results between the app and using mrgsolve in R. GPKPDviz is a member of the suite of Modeling and Simulation Shiny apps developed at Genentech to facilitate the typical modeling work in Clinical Pharmacology. For broader access to the Pharmacometric community, gPKPDviz has been published as an open‐source application in GitHub under the terms of GNU General Public License.


  • Open Access

    Concentration QTc analysis of giredestrant: Overcoming QT/heart rate confounding in the presence of drug‐induced heart rate changes

    by Logan Brooks, Michael Dolton, Jurgen Langenhorst, Kenta Yoshida, Yi Ting (Kayla) Lien, Vikram Malhi, Chunze Li, Pablo Perez‐Moreno, John Bond, Ya‐Chi Chen, et al.

    Concentration‐QTc (C‐QTc) analysis has become a common approach for evaluating proarrhythmic risk and delayed cardiac repolarization of oncology drug candidates. Significant heart rate (HR) change has been associated with certain classes of oncology drugs and can result in over‐ or underestimation of the true QT prolongation risk. Because oncology early clinical trials typically lack a placebo control arm or time‐matched, treatment‐free baseline electrocardiogram collection, significant HR change brings additional challenges to C‐QTc analysis in the oncology setting. In this work, a spline‐based correction method (QTcSPL) was explored to mitigate the impact of HR changes in giredestrant C‐QTc analysis. Giredestrant is a selective estrogen receptor degrader being developed for the treatment of patients with estrogen receptor‐positive (ER+) breast cancer. A dose‐related HR decrease has been observed in patients under giredestrant treatment, with significant reductions (>10 bpm) observed at supratherapeutic doses. The QTcSPL method demonstrated superior functionality to reduce the correlation between QTc and HR as compared with the Fridericia correction (QTcF). The effect of giredestrant exposure on QTc was evaluated at the clinical dose of 30 mg and supratherapeutic dose of 100 mg based on a prespecified linear mixed effect model. The upper 90% confidence interval of ΔQTcSPL and ΔQTcF were below the 10 ms at both clinical and supratherapeutic exposures, suggesting giredestrant has a low risk of QT prolongation at clinically relevant concentrations. This work demonstrated the use case of QTcSPL to address HR confounding challenges in the context of oncology drug development for the first time.